Replies to post #39734 on RespireRx Pharmaceuticals Inc (RSPI)

[GetSeriousOK]

Manuso says he is "[looking] forward to discussing preliminary, top-line results of the Company’s recently concluded Phase 2A clinical trial testing the impact of the Company’s proprietary oral ampakine, CX-1739, on opioid-induced respiratory depression" at Rodman and Redshaw on Monday the 12th?

http://respirerx.com/respirerx-pharmaceuticals-inc-to-present-at-the-rodman-renshaw-18th-annual-global-investment-conference-on-september-12-2016/

The dronabinol results are pushed back to Q4. That's not Manuso's fault, and that does not, in my mind, indicate a failure to meet endpoints.

I think we ALL expected the dronabinol news before the R/S, including Manuso, but I think Manuso wanted the attractive share structure and PPS when he presents at Rodman & Redshaw. We'll find out Monday/Tuesday whether the R/S coming first was a smart move by Manuso.